Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 20/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 20/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 19/20 | 0.60 |
| ▸ | CLK4 | Q9HAZ1 | 17/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 18/20 | 0.56 |
| ▸ | TSHR | P16473 | 9/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.56 |
| ▸ | LMNA | P02545 | 5/20 | 0.56 |
| ▸ | USP2 | O75604 | 11/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 6/20 | 0.55 |
| ▸ | MEN1 | O00255 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15343114 | 0.84 | CYP1A2 (0.57) | CYP1A2CYP3A4CYP2D6CLK4CYP2C19 | |
| SCHEMBL15342952 | 0.82 | CYP1A2 (0.61) | CYP1A2CYP3A4CYP2D6CLK4CYP2C19 | |
| SCHEMBL16664962 | 0.79 | CLK4 (0.44) | CYP1A2CYP3A4CYP2D6CLK4CYP2C19 | |
| SCHEMBL15342953 | 0.75 | CYP1A2 (0.55) | CYP1A2CYP3A4CYP2D6CLK4CYP2C19 | |
| SCHEMBL4107358 | 0.74 | PTGDR (0.63) | CYP1A2CYP3A4CYP2D6CLK4CYP2C19 | |
| SCHEMBL19355263 | 0.74 | CLK4 (0.41) | CYP1A2CYP3A4CYP2D6CLK4CYP2C19 | |
| SCHEMBL15343087 | 0.73 | AURKA (0.56) | CYP1A2CYP3A4CYP2D6CLK4CYP2C19 | |
| SCHEMBL22027964 | 0.73 | CYP1A2 (0.50) | CYP1A2CYP3A4CYP2D6CLK4CYP2C19 | |
| SCHEMBL15342946 | 0.71 | CYP1A2 (0.49) | CYP1A2CYP3A4CYP2D6CLK4CYP2C19 | |
| SCHEMBL15343088 | 0.71 | CYP1A2 (0.51) | CYP1A2CYP3A4CYP2D6CLK4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10391095-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10391095-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | CYP1A2 2215/4885CYP3A4 1759/4885CYP2D6 984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.